Results 31 to 40 of about 18,455 (220)

Lutathera^®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy

Pharmaceuticals, 2019
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.
Ute Hennrich, Klaus Kopka
doaj   +1 more source

Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma

Clinical and Translational Radiation Oncology, 2020
Background: The combination of somatostatin receptor-directed peptide receptor radionuclide therapy (PRRT) in combination with external beam radiotherapy (EBRT) might prove a feasible treatment option in patients with advanced meningioma.
Philipp E. Hartrampf, Heribert Hänscheid, Olivia Kertels, Andreas Schirbel, Michael C. Kreissl, Michael Flentje, Reinhart A. Sweeney, Andreas K. Buck, Bülent Polat, Constantin Lapa   +9 more
doaj   +1 more source

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Frontiers in Medicine, 2022
Peptide receptor radionuclide therapy (PRRT) has over the last two decades emerged as a very promising approach to treat neuroendocrine tumors (NETs) with rapidly expanding clinical applications. By chelating a radiometal to a somatostatin receptor (SSTR)
Mengqi Shi, Mengqi Shi, Vivianne Jakobsson, Vivianne Jakobsson, Lukas Greifenstein, Pek-Lan Khong, Pek-Lan Khong, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Xiaoyuan Chen, Richard P. Baum, Jingjing Zhang, Jingjing Zhang, Jingjing Zhang   +15 more
doaj   +1 more source

Treatment of a mixed acinar-endocrine carcinoma with uptake on 68Gallium-DOTATOC positron emission tomography-computed tomography : a case report [PDF]

, 2017
The case of a 35-year old female patient with a diagnosis of metastatic mixed acinar-endocrine carcinoma (MAEC) is investigated in the present study.
De Both, Anneleen, De Man, Marc, Geboes, Karen, Hoorens, Anne, Troisi, Roberto, Van Vlierberghe, Hans   +5 more
core   +2 more sources

Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review

EJNMMI Research, 2018
Background The main challenge for systemic radiation therapy using radiopharmaceuticals (SRT) is to optimise the dose delivered to the tumour, while minimising normal tissue irradiation.
Daphne Merel Valerie Huizing, Berlinda Jantina de Wit-van der Veen, Marcel Verheij, Marcellus Petrus Maria Stokkel   +3 more
doaj   +1 more source

Blood-brain barrier transport kinetics of NOTA-modified proteins : the somatropin case [PDF]

, 2020
BACKGROUND: Chemical modifications such as PEG, polyamine and radiolabeling on proteins can alter their pharmacokinetic behaviour and their blood-brain barrier (BBB) transport characteristics. NOTA, i.e. 1,4,7-triazacyclononane-1,4,7-triacetic acid, is a
Bracke, Nathalie, De Spiegeleer, Bart, Janssens, Yorick, Maes, Alex, Sathekge, Mike, Tack, Liesa, Van De Wiele, Christophe, Wynendaele, Evelien   +7 more
core   +1 more source

Peptide receptor radionuclide therapy

, 2015
Peptide receptor radionuclide therapy (PRRT) is an internal radiation therapy which is based on specific binding of therapeutic radiopharmaceutical to somatostatin receptor (mostly sstr2) and internalization of receptor-radiopharmaceutical complex to exert radiation damage to neuroendocrine tumour cells.
Stefańska, Agnieszka, Hubalewska-Dydejczyk, Alicja, Jabrocka-Hybel, Agata, Sowa-Staszczak, Anna   +3 more
  +5 more sources

Preclinical efficacy of hK2 targeted [177Lu]hu11B6 for prostate cancer theranostics [PDF]

, 2019
Androgen ablating drugs increase life expectancy in men with metastatic prostate cancer, but resistance inevitably develops. In a majority of these recurrent tumors, the androgen axis is reactivated in the form of increased androgen receptor (AR ...
Beattie, Bradley J., Beattie, Kai A., Elgqvist, Jörgen, Eriksson, Sophie E., Larsson, Erik, Strand, Sven-Erik, Thorek, Daniel L. J., Timmermand, Oskar Vilhelmsson, Tran, Thuy A., Ulmert, David, Örbom, Anders   +10 more
core   +2 more sources

Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison [PDF]

, 2011
The development of suitable radioligands for targeting CCK-2 receptor expressing tumors, such as medullary thyroid carcinoma, is of great clinical interest.
ACCARDO, ANTONELLA, Aloj L., Arra C, Aurilio M, Barbieri A, MORELLI, GIANCARLO, Tarallo L, TESAURO, DIEGO, Tornesello AL   +8 more
core   +1 more source

Demonstration of focal physiologic in-vivo somatostatin receptor expression in the caput epididymis of the testes on 68Ga-DOTANOC PET/CT and 177Lu-DOTATATE post-therapy whole body scintigraphy [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2020
We present the case of a 60-year-old man with metastatic neuroendocrine tumor of the ileum following ileal resection, being evaluated for 177Lu-based peptide receptor radionuclide therapy.
Ashwin Parihar, Apurva Sood, Ashwani Sood, Ajay Gulati, Bhagwant Mittal   +4 more
doaj   +1 more source